Evidence map›Paper›PMID 32974208›Full record

ArticleFrontiers in oncology2020

Moderately Hypofractionated Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Prostate Cancer: Five-Year Toxicity Results From a Prospective Phase I/II Trial.

Anthony Ricco, Nitai Mukhopadhyay, Xiaoyan Deng, Diane Holdford, Vicki Skinner, Siddharth Saraiya, Drew Moghanaki, Mitchell S Anscher, Michael G Chang

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01117935 (Study of Hypofractionated Intensity Modulated External Beam Therapy for the Treatment of Patients With Adenocarcinoma of the Prostate), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01117935 nacompletednot on this map

Study of Hypofractionated Intensity Modulated External Beam Therapy for the Treatment of Patients With Adenocarcinoma of the Prostate

TypeinterventionalSponsorVirginia Commonwealth UniversityRan2010 to 2019Enrolled55ConditionsAdenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate CancerArmsintensity modulated external beam radiation therapy
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anthony RiccoMassey Cancer Center, Department of Radiation Oncology, Virginia Commonwealth University Health System, Richmond, VA, United States.
Nitai MukhopadhyayDepartment of Biostatistics, Virginia Commonwealth University, Richmond, VA, United States.
Xiaoyan DengDepartment of Biostatistics, Virginia Commonwealth University, Richmond, VA, United States.
Diane HoldfordVirginia Commonwealth University Health System, Virginia Commonwealth University, Richmond, VA, United States.
Vicki SkinnerHunter Holmes McGuire Veterans Administration Medical Center, Richmond, VA, United States.
Siddharth SaraiyaMassey Cancer Center, Department of Radiation Oncology, Virginia Commonwealth University Health System, Richmond, VA, United States.
Drew MoghanakiMassey Cancer Center, Department of Radiation Oncology, Virginia Commonwealth University Health System, Richmond, VA, United States.
Mitchell S AnscherMassey Cancer Center, Department of Radiation Oncology, Virginia Commonwealth University Health System, Richmond, VA, United States.
Michael G ChangMassey Cancer Center, Department of Radiation Oncology, Virginia Commonwealth University Health System, Richmond, VA, United States.

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Keri R Maher · 1985 to 2026
$51.0M
NCI NIH HHS P30 CA016059
6 · The paper itself

Abstract

backgroundIn this phase I/II trial, 5-year physician-assessed toxicity and patient reported quality of life data is reported for patients undergoing moderately hypofractionated intensity modulated radiation therapy (IMRT) for prostate cancer using a simultaneous integrated boost (SIB) and pelvic lymph node (LN) coverage. MATERIALS AND

methodsPatients with T1-T2 localized prostate cancer were prospectively enrolled, receiving risk group based coverage of prostate ± seminal vesicles (SVs) ± pelvic lymph nodes (LNs). Low risk (LR) received 69.6 Gy/29 fractions to the prostate, while intermediate risk (IR) and high risk (HR) patients received 72 Gy/30fx to the prostate and 54Gy/30fx to the SVs. If predicted risk of LN involvement >15%, 50.4 Gy/30fx was delivered to pelvic LNs. Androgen deprivation therapy was given to IR and HR patients.

resultsThere were 55 patients enrolled and 49 patients evaluable at a median follow up of 60 months. Included were 11 (20%) LR, 23 (41.8%) IR, and 21 (38.2%) HR patients. Pelvic LN treatment was given in 25 patients (51%). Prevalence rates of late grade 2 GI toxicity at 1, 3, and 5 years was 5.8, 3.9, and 5.8%, respectively, with no permanent grade 3 events. Prevalence rates of late grade 2 GU toxicity at 1, 3, and 5 years rates were 15.4, 7.7, and 13.5%, respectively, with three grade 3 events (5.8%). The biochemical relapse free survival at 5 years was 88.3%. There were no local, regional, or distant failures, with all patients still alive at last follow up.

conclusionModerate hypofractionation of localized prostate cancer utilizing a SIB technique and LN coverage produces tolerable acute/late toxicity. Given equivalent efficacy between moderate hypofractionation schedules, the optimal regimen will be determined by long-term toxicity reported from both the physician and patient perspective. CLINICAL

trial registrationwww.ClinicalTrials.gov, identifier NCT01117935, Date of Registration: 5/6/2010.

Indexed as

clinical trialgastrointestinal toxicitygenitourinary toxicitymoderate hypofractionationpatient reported outcome measurespelvic lymph nodesprostate radiation therapysimultaneous integrated boost

Identifiers

PMID32974208
PMCPMC7471868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.